EntryPoint Capital LLC Invests $423,000 in AMNEAL PHARMACEUTICALS, INC. $AMRX

Key Points

• EntryPoint Capital LLC invested approximately $423,000 in Amneal Pharmaceuticals, acquiring 50,530 shares in the company during the first quarter.
• Several institutional investors, including Janney Montgomery Scott LLC and Allspring Global Investments Holdings LLC, have significantly increased their positions in Amneal Pharmaceuticals, indicating growing institutional interest.
• Amneal Pharmaceuticals recently reported a quarterly earnings per share (EPS) of $0.23, outperforming analyst estimates and setting FY 2025 guidance at $0.700-$0.750 EPS.

EntryPoint Capital LLC acquired a new position in shares of AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 50,530 shares of the company's stock, valued at approximately $423,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of AMNEAL PHARMACEUTICALS by 6.2% in the first quarter. Vanguard Group Inc. now owns 15,762,727 shares of the company's stock worth $132,092,000 after acquiring an additional 920,758 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of AMNEAL PHARMACEUTICALS by 5.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 4,991,702 shares of the company's stock worth $39,531,000 after acquiring an additional 278,653 shares during the last quarter. Nantahala Capital Management LLC raised its holdings in shares of AMNEAL PHARMACEUTICALS by 37.3% in the fourth quarter. Nantahala Capital Management LLC now owns 3,665,529 shares of the company's stock worth $29,031,000 after acquiring an additional 995,586 shares during the last quarter. Nuveen LLC acquired a new position in shares of AMNEAL PHARMACEUTICALS in the first quarter worth $19,581,000. Finally, Invesco Ltd. raised its holdings in shares of AMNEAL PHARMACEUTICALS by 19.2% in the first quarter. Invesco Ltd. now owns 2,272,713 shares of the company's stock worth $19,045,000 after acquiring an additional 365,467 shares during the last quarter. 31.82% of the stock is owned by institutional investors and hedge funds.

Insider Activity at AMNEAL PHARMACEUTICALS

In related news, EVP Nikita Shah sold 114,492 shares of the company's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $9.66, for a total transaction of $1,105,992.72. Following the completion of the sale, the executive vice president directly owned 152,743 shares of the company's stock, valued at approximately $1,475,497.38. This represents a 42.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jason B. Daly sold 22,000 shares of the stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $9.05, for a total value of $199,100.00. Following the completion of the sale, the executive vice president owned 10,606 shares of the company's stock, valued at approximately $95,984.30. This represents a 67.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 577,206 shares of company stock worth $5,405,265. 17.45% of the stock is currently owned by corporate insiders.

AMNEAL PHARMACEUTICALS Stock Performance

Shares of NASDAQ:AMRX traded up $0.07 during trading on Tuesday, reaching $9.35. 170,701 shares of the stock were exchanged, compared to its average volume of 1,675,191. The firm's 50-day moving average price is $8.40 and its 200 day moving average price is $8.02. The firm has a market cap of $2.94 billion, a price-to-earnings ratio of 935.44 and a beta of 1.11. AMNEAL PHARMACEUTICALS, INC. has a 12-month low of $6.68 and a 12-month high of $9.79.

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.17 by $0.06. AMNEAL PHARMACEUTICALS had a net margin of 0.12% and a negative return on equity of 189.49%. AMNEAL PHARMACEUTICALS has set its FY 2025 guidance at 0.700-0.750 EPS. As a group, equities research analysts forecast that AMNEAL PHARMACEUTICALS, INC. will post 0.53 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Wall Street Zen cut AMNEAL PHARMACEUTICALS from a "strong-buy" rating to a "buy" rating in a report on Tuesday, May 13th. The Goldman Sachs Group started coverage on AMNEAL PHARMACEUTICALS in a research note on Friday, June 6th. They issued a "buy" rating and a $12.00 target price for the company. Five research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $11.60.

AMNEAL PHARMACEUTICALS Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.